Protalix BioTherapeutics, Inc. (PLX) Insider Trading Disclosures
Protalix BioTherapeutics, Inc. (PLX) is a publicly traded company on the NYSE, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: PLX
CIK: 1006281
Exchange: NYSE
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Kesselman & Kesselman C.P.A.s
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerKeren Shlomo Zaaror
Audit LocationTel-Aviv, Israel
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G | 2026-10-15 | — | SCHEDULE 13G Filing | 0002086358-26-000006 | View SEC Doc Filr Page |
| 4 | 2026-09-09 | 2026-09-03 | 4 Filing | 0001178913-26-004471 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0001742727-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0002075661-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0001614890-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0001454771-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0001781450-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0001385113-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0001935668-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-09-04 | 2026-09-03 | 4 Filing | 0001831558-26-000003 | View SEC Doc Filr Page |
| S-8 | 2026-08-12 | — | FORM S-8 | 0001104659-26-094487 | View SEC Doc Filr Page |
| 10-Q | 2026-08-12 | 2026-06-30 | 10-Q | 0001104659-26-094444 | View SEC Doc Filr Page |
| 8-K | 2026-08-12 | 2026-08-12 | 8-K | 0001104659-26-094433 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-29 | — | SCHEDULE 13G Filing | 0002012383-26-002863 | View SEC Doc Filr Page |
| 8-K | 2026-06-25 | 2026-06-25 | 8-K | 0001104659-26-077790 | View SEC Doc Filr Page |
| 8-K | 2026-05-21 | 2026-05-21 | 8-K | 0001104659-26-064850 | View SEC Doc Filr Page |
| 10-Q | 2026-05-13 | 2026-03-31 | 10-Q | 0001104659-26-059756 | View SEC Doc Filr Page |
| 8-K | 2026-05-13 | 2026-05-13 | 8-K | 0001104659-26-059749 | View SEC Doc Filr Page |
| ARS | 2026-04-30 | 2025-12-31 | ARS | 0001104659-26-053038 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-30 | 2026-06-25 | DEF 14A | 0001104659-26-053016 | View SEC Doc Filr Page |
| 3/A | 2026-04-27 | 2025-08-24 | 3/A Filing | 0001975896-26-000003 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-03-30 | — | SCHEDULE 13G/A Filing | 0001426156-26-000006 | View SEC Doc Filr Page |
| 10-K | 2026-03-18 | 2025-12-31 | 10-K | 0001104659-26-029858 | View SEC Doc Filr Page |
| 8-K | 2026-03-18 | 2026-03-18 | 8-K | 0001104659-26-029846 | View SEC Doc Filr Page |
| 8-K | 2026-03-09 | 2026-03-09 | 8-K | 0001104659-26-024975 | View SEC Doc Filr Page |